Cargando…

Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T(3-4a)N0M0 Gastric Cancer Patients after D2 Gastrectomy

Aim. To investigate whether tumor size is a reasonable indication for adjuvant chemotherapy for T(3-4a)N0M0 gastric cancer patients after D2 gastrectomy. Method. We performed a retrospective study of 269 patients with a histological diagnosis of T(3-4a)N0M0 stage gastric cancer who underwent D2 radi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shi, Ou-Yang, Li-Ying, Nie, Run-Cong, Li, Yuan-Fang, Xiang, Jun, Zhou, Zhi-Wei, Chen, Ying-Bo, Peng, Jun-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346364/ https://www.ncbi.nlm.nih.gov/pubmed/28331491 http://dx.doi.org/10.1155/2017/4928736

Ejemplares similares

Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy
por: Shao, Xinxin, et al.
Publicado: (2023)

Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer?
por: Huang, Jiao-Bao, et al.
Publicado: (2021)

A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy
por: Xu, Quan, et al.
Publicado: (2022)

Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis
por: Yuan, Shu-Qiang, et al.
Publicado: (2017)

Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer after D2 Gastrectomy
por: Jin, Ying, et al.
Publicado: (2013)

Survival analysis of stage II gastric cancer patients after D2 gastrectomy: a Chinese people-based research
por: Deng, Zi-Jian, et al.
Publicado: (2021)

Nomogram analysis and external validation to predict the risk of lymph node metastasis in gastric cancer
por: Chen, Shi, et al.
Publicado: (2017)

Body mass index (BMI) may be a prognostic factor for gastric cancer with peritoneal dissemination
por: Chen, Shi, et al.
Publicado: (2017)

Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
por: Wu, Chenghui, et al.
Publicado: (2023)

Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study
por: Mei, Yu, et al.
Publicado: (2022)

Effect of laparoscopic gastrectomy on compliance with adjuvant chemotherapy in patients with gastric cancer
por: Bao, Huizheng, et al.
Publicado: (2017)

Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer—an east and west multicenter study
por: Huang, Ze-Ning, et al.
Publicado: (2019)

Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection
por: Li, Xiao-hui, et al.
Publicado: (2022)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Additional gastrectomy in early-stage gastric cancer after non-curative endoscopic resection: a meta-analysis
por: Nie, Run-Cong, et al.
Publicado: (2019)

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy
por: Fu, Wen-Fen, et al.
Publicado: (2020)

Reply to Graziosi et al. Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on “Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. J. Pers. Med. 2023, 13, 553”
por: Chen, Yi-Fu, et al.
Publicado: (2023)

Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
por: You, Kai-yun, et al.
Publicado: (2014)

Clinical impact of postoperative interval until adjuvant chemotherapy following curative gastrectomy for advanced gastric cancer
por: Takashima, Yusuke, et al.
Publicado: (2021)

Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer
por: Yuan, Shu‐Qiang, et al.
Publicado: (2023)

Indication for and Effect of Adjuvant Chemotherapy for Stage IIa (T3N0M0) Colon Cancer
por: Jeon, Chul-Hyo, et al.
Publicado: (2019)

Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy
por: Wu, Bin, et al.
Publicado: (2014)

A Novel Inflammatory-Nutritional Prognostic Scoring System for Stage III Gastric Cancer Patients With Radical Gastrectomy Followed by Adjuvant Chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
por: Serrano, Mariana, et al.
Publicado: (2022)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
por: Kim, Young Saing, et al.
Publicado: (2017)

Why a D2 gastrectomy plus adjuvant chemotherapy is insufficient in locally advanced gastric cancer
por: Sebastián Solé, Z, et al.
Publicado: (2016)

Predictive Role of Endoscopic Surveillance after Total Gastrectomy with R0 Resection for Gastric Cancer
por: Lee, Jung Su, et al.
Publicado: (2021)

The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis
por: Zhong, Qiulu, et al.
Publicado: (2023)

Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. J. Pers. Med. 2023, 13, 553
por: Graziosi, Luigina, et al.
Publicado: (2023)

Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer
por: Wang, Qi-Wei, et al.
Publicado: (2018)

Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy
por: Bang, Hyun Jin, et al.
Publicado: (2023)

Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis
por: Chen, Xiao-Jiang, et al.
Publicado: (2021)

Is adjuvant chemotherapy necessary for patients with ypT0–2N0 rectal cancer treated with neoadjuvant chemoradiotherapy and curative surgery?
por: Lu, Zhao, et al.
Publicado: (2018)

Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
por: Ren, Deng-Feng, et al.
Publicado: (2018)

Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy
por: Cho, Jang Ho, et al.
Publicado: (2017)

Preoperative Splenic Density for the Prediction of Survival and Adjuvant Chemotherapy Benefits in Gastric Cancer
por: Zhang, Wei-teng, et al.
Publicado: (2020)

Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer
por: Zhai, Zhen, et al.
Publicado: (2020)

The sintering temperature effect on electrochemical properties of Ce(0.8)Sm(0.05)Ca(0.15)O(2-δ) (SCDC)-La(0.6)Sr(0.4)Co(0.2)Fe(0.8)O(3-δ) (LSCF) heterostructure pellet
por: Nie, Xiyu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3cs7f3056dltdhceeisb6dcnrj